None listed
Conditions
Interventions
Randomised, placebo-controlled, cross-over investigation. There will be two phases during which beta agonist will or will not be given on a regular basis. Each phase will last a month, with a 1-2 week washout period inbetween. At each visit, 2 bronchial challenges will be administered and either placebo, anti-cholinergic or beta-agonist relief will be given.
Sponsors
Otago Medical Research Foundation
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
12 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Asthma (according to the ATS), Non-smokers.
Exclusion criteria
Pregnancy, high dose ICS, history of life-threatening asthma, unable to tolerate ipratropium as a reliever inhaler, recent use of oral steroids, LRTI.
Outcome results
None listed